[{"orgOrder":0,"company":"Abbisko Therapeutics","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Small molecule","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Discovery","graph3":"Abbisko Therapeutics","amount2":0.26000000000000001,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.26000000000000001,"dosageForm":"","sponsorNew":"Abbisko Therapeutics \/ Eli Lilly","highestDevelopmentStatusID":"2","companyTruncated":"Abbisko Therapeutics \/ Eli Lilly"},{"orgOrder":0,"company":"Abbisko Therapeutics","sponsor":"Shanghai Allist Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Licensing Agreement","leadProduct":"ABK3376","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Abbisko Therapeutics","amount2":0.19,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0.19,"dosageForm":"","sponsorNew":"Abbisko Therapeutics \/ Shanghai Allist Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Abbisko Therapeutics \/ Shanghai Allist Pharmaceuticals"},{"orgOrder":0,"company":"Abbisko Therapeutics","sponsor":"Merck Group","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Pimicotinib","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Abbisko Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Abbisko Therapeutics \/ Merck Group","highestDevelopmentStatusID":"10","companyTruncated":"Abbisko Therapeutics \/ Merck Group"},{"orgOrder":0,"company":"Abbisko Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Pimicotinib","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Abbisko Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Abbisko Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Abbisko Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Abbisko Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Pimicotinib","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Abbisko Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Abbisko Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Abbisko Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Abbisko Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Pimicotinib","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Abbisko Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Abbisko Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Abbisko Therapeutics \/ Not Applicable"}]

Find Clinical Drug Pipeline Developments & Deals by Abbisko Therapeutics

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          CPhI India 2024
                          Not Confirmed
                          CPhI India 2024
                          Not Confirmed

                          Details : ABSK021 (pimicotinib) is a novel, orally available, highly selective, and potent small molecule CSF-1R inhibitor. It is being evaluated for for the treatment of tenosynovial giant cell tumor.

                          Brand Name : ABSK021

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          November 11, 2024

                          Lead Product(s) : Pimicotinib

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase III

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          02

                          CPhI India 2024
                          Not Confirmed
                          CPhI India 2024
                          Not Confirmed

                          Details : ABSK021 (pimicotinib) is a selective CSF-1R inhibitor currently in phase 3 studies for treating inoperable tenosynovial giant cell tumors.

                          Brand Name : ABSK021

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          January 08, 2024

                          Lead Product(s) : Pimicotinib

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase III

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          03

                          CPhI India 2024
                          Not Confirmed
                          CPhI India 2024
                          Not Confirmed

                          Details : ABSK021 (pimicotinib) is a novel, orally available, highly selective, and potent small molecule CSF-1R inhibitor. It is being evaluated for for the treatment of tenosynovial giant cell tumor (TGCT).

                          Brand Name : ABSK021

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          December 13, 2023

                          Lead Product(s) : Pimicotinib

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase III

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          04

                          CPhI India 2024
                          Not Confirmed
                          CPhI India 2024
                          Not Confirmed

                          Details : Under the agreement, Merck will receive an exclusive license to commercialize ABSK021 (pimicotinib), an oral, highly selective and potent small-molecule antagonist of colony stimulating factor-1 receptor, currently in Phase III for tenosynovial giant cel...

                          Brand Name : ABSK021

                          Molecule Type : Small molecule

                          Upfront Cash : $70.0 million

                          December 04, 2023

                          Lead Product(s) : Pimicotinib

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase III

                          Sponsor : Merck Group

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          blank

                          05

                          CPhI India 2024
                          Not Confirmed
                          CPhI India 2024
                          Not Confirmed

                          Details : The licensed small-molecule antagonist of EGFR ABK3376 is a pre-clinical candidate developed by Abbisko Therapeutics' proprietary drug discovery platform, which is a novel, highly potent, selective, and brain-penetrating new-generation EGFR inhibitor.

                          Brand Name : ABK3376

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          March 01, 2023

                          Lead Product(s) : ABK3376,Furmonertinib

                          Therapeutic Area : Oncology

                          Highest Development Status : Preclinical

                          Sponsor : Shanghai Allist Pharmaceuticals

                          Deal Size : $187.9 million

                          Deal Type : Licensing Agreement

                          blank

                          06

                          CPhI India 2024
                          Not Confirmed
                          CPhI India 2024
                          Not Confirmed

                          Details : Under the terms of the Agreement, Abbisko Therapeutics will be responsible for the further discovery and development of molecules that modulate a novel and challenging drug target using its proprietary R&D platform.

                          Brand Name : Undisclosed

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          January 18, 2022

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Discovery

                          Sponsor : Eli Lilly

                          Deal Size : $258.0 million

                          Deal Type : Collaboration

                          blank